Regeneus Ltd

Regeneus is an Australian biotechnology company aiming to improve the quality of life of the hundreds of millions of patients worldwide suffering from long and short term pain.

Pain and inflammation are responsible for a series of events leading to immune cells reacting to damaged tissue, causing chronic and acute illness.

The Company develops regenerative medicine products that interrupt the inflammatory cascade that leads to pain, including its two leading stem cell technologies, Progenza™ – which has been licenced to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus – which is in pre-clinical stage.